...
首页> 外文期刊>Toxicology and Applied Pharmacology >XRCC1 Arg194Trp and Arg399Gln polymorphisms and arsenic methylation capacity are associated with urothelial carcinoma
【24h】

XRCC1 Arg194Trp and Arg399Gln polymorphisms and arsenic methylation capacity are associated with urothelial carcinoma

机译:XRCC1 Arg194Trp和Arg399Gln多态性和砷甲基化能力与尿路上皮癌相关

获取原文
获取原文并翻译 | 示例

摘要

The association between DNA repair gene polymorphisms and bladder cancer has been widely studied. However, few studies have examined the correlation between urothelial carcinoma (UC) and arsenic or its metabolites. The aim of this study was to examine the association between polymorphisms of the DNA repair genes, XRCC1 Arg194Trp, XRCC1 Arg399Gln, XRCC3 Thr241Met, and XPD Lys751Gln, with urinary arsenic profiles and UC. To this end, we conducted a hospital-based case-control study with 324 UC patients and 647 age- and gender-matched non-cancer controls. Genomic DNA was used to examine the genotype of XRCC1 Arg194Trp, XRCC1 Arg399Gln, XRCC3 Thr241Met, and XPD Lys751Gln by PCR-restriction fragment length polymorphism analysis (PCR-RFLP). Urinary arsenic profiles were measured by high performance liquid chromatography (HPLC) linked with hydride generator and atomic absorption spectrometry. The XRCC1 399 Gln/Gln and 194 Arg/Trp and Trp/Trp genotypes were significantly related to UC, and the odds ratio (OR) and 95% confidence interval (95%CI) were 1.68 (1.03-2.75) and 0.66(0.48-0.90), respectively. Participants with higher total urinary arsenic levels, a higher percentage of inorganic arsenic (InAs%) and a lower percentage of dimethylarsinic acid (DMA%) had a higher OR of UC. Participants carrying XRCC1 risk diplotypes G-C/G-C, A-C/A-C, and A-T/G-T, and who had higher total arsenic levels, higher InAs%, or lower DMA% compared to those with other XRCC1 diplotypes had a higher OR of UC. Our results suggest that the XRCC1 399 Gln/Gln and 194 Arg/Arg DNA repair genes play an important role in poor arsenic methylation capacity, thereby increasing the risk of UC in non-obvious arsenic exposure areas. (C) 2014 Elsevier Inc. All rights reserved.
机译:DNA修复基因多态性与膀胱癌之间的关联已被广泛研究。但是,很少有研究检查尿路上皮癌(UC)与砷或其代谢产物之间的相关性。这项研究的目的是检查DNA修复基因,XRCC1 Arg194Trp,XRCC1 Arg399Gln,XRCC3 Thr241Met和XPD Lys751Gln多态性与尿中砷和UC的关联。为此,我们对324名UC患者和647名年龄和性别匹配的非癌症对照者进行了一项基于医院的病例对照研究。通过PCR-限制性片段长度多态性分析(PCR-RFLP),使用基因组DNA检查XRCC1 Arg194Trp,XRCC1 Arg399Gln,XRCC3 Thr241Met和XPD Lys751Gln的基因型。通过与氢化物发生剂连接的高效液相色谱(HPLC)和原子吸收光谱法测量尿中砷的分布。 XRCC1 399 Gln / Gln和194 Arg / Trp和Trp / Trp基因型与UC显着相关,优势比(OR)和95%置信区间(95%CI)分别为1.68(1.03-2.75)和0.66(0.48) -0.90)。总尿中砷水平较高,无机砷(InAs%)较高和二甲基砷酸(DMA%)较低的参与者的UC较高。与其他XRCC1双倍型相比,携带XRCC1双倍型G-C / G-C,A-C / A-C和A-T / G-T的参与者具有更高的总砷水平,更高的InAs%或更低的DMA%。我们的研究结果表明,XRCC1 399 Gln / Gln和194 Arg / Arg DNA修复基因在不良的砷甲基化能力中起重要作用,从而增加了非明显砷暴露区域中UC的风险。 (C)2014 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号